GeneMind has raised nearly RMB 400 million in a Series C funding round, which it will put toward expanding the research and development of its products and applications, broadening the portfolio of products, and scaling up its current capacity. GeneMind will also use the funding from its Series C round to accelerate regulatory approval and adoption of its sequencing platforms and reagents in domestic and overseas markets.
KingMed Diagnostics and Guoxin Investment led the round, joined by Shenzhen HTI Group, National Medtech Odyssey Ventures, Changzhou Shuangye Venture Capital, and Caixin Capital.
We remain committed to building a precision medical ecosystem that serves healthcare through collaborations with genetic testing service providers and medical institutions. With this funding, we can embark on the next stage of our development and take our collaborative approach further, improving the sequencing industry together.
